New recommendations call for regular PSA testing among men aged 50–69, with earlier screening for higher-risk groups and additional safeguards to reduce unnecessary biopsies and treatment.
Prostate cancer screening is the practice of testing men who have no symptoms in order to find prostate cancer before it causes problems. The most common screening tool is the prostate-specific antigen (PSA) blood test. On November 12, 2026, the American Cancer Society (ACS) updated its prostate cancer screening guidelines. This is the organisation’s first major revision since 2010. The ACS now recommends regular PSA testing for men at average risk between the ages of 50 and 69. Black men and men with a strong family history should start earlier, at age 45.
This article explains who should be tested, how often, what an elevated result means and why active surveillance now plays a larger part in care.
What the Updated ACS Guidelines Recommend
Under the revised guidance, men at average risk should have PSA-based screening every two years. Black men and men with a strong family history of prostate cancer should begin at age 45. Annual testing is recommended for those at higher risk.
The change rests on growing evidence that PSA-based screening can reduce prostate cancer deaths and help find advanced-stage disease sooner. The ACS also points to better follow-up testing and cancer management, which lower the risks that come with unnecessary biopsies and treatment.
The scale of the disease explains why this matters. The ACS estimates that 333,830 men in the United States will be diagnosed with prostate cancer in 2026, and about 36,320 are expected to die from it. Prostate cancer remains one of the most common cancers among men and the second-leading cause of cancer-related deaths in this population in the country.
Who Should Begin Prostate Cancer Screening Earlier?
The revised recommendations separate average-risk men from higher-risk men. For men at average risk, the ACS recommends a PSA blood test every two years between ages 50 and 69. Certain groups should start at 45:
- Black men.
- Non-Black men with a strong family history, such as a father, brother or son diagnosed before age 65, or several first-degree relatives diagnosed with prostate cancer.
- Non-Black men with one first-degree relative diagnosed at age 65 or older. These men should also begin at 45 and test every two years through age 69.
The guidance for older men is more cautious, and the table below sets out each age group.
| Age group | ACS recommendation |
|---|---|
| 45 to 69 (higher risk, as listed above) | Begin screening at 45 and continue through 69. Annual testing is recommended for those at higher risk. |
| 50 to 69 (average risk) | PSA blood test every two years |
| 70 to 74 | Individualised decision after discussing benefits and risks with a healthcare provider |
| 75 to 79 | No routine screening. Exceptionally healthy men may discuss continued testing with their doctors. |
| 80 and older, or life expectancy below 10 years | Screening discouraged |
The age limits exist because slow-growing prostate cancers often take many years to cause harm. A man with a short life expectancy is more likely to experience the downsides of testing and treatment than to gain from them.
What Happens When a PSA Test Shows Elevated Levels?
PSA is a protein made by cells in the prostate gland. The test measures how much of it is in the blood, reported in nanograms per millilitre (ng/mL). Elevated levels can point to prostate cancer, but an enlarged prostate or inflammation can also raise PSA. For this reason, a single high number is a prompt for more questions and not a diagnosis.
The ACS recommends repeating an elevated PSA test within two weeks to three months before any further investigation. The guideline defines an elevated result by age:
- Ages 45 to 69: 3.0 ng/mL or higher.
- Ages 70 to 74: 6.5 ng/mL or higher.
If the repeat test confirms the elevation, doctors should offer prostate magnetic resonance imaging (MRI), validated biomarker testing, or both. These steps help decide whether a biopsy is truly needed.
The aim is to cut back on invasive procedures. Prostate biopsies can cause bleeding and infection, and false-positive results can bring anxiety and a chain of extra tests. An elevated PSA result does not automatically mean a man has prostate cancer or needs a biopsy.
Several everyday factors can also move a PSA reading, and men can raise them with their doctor before a test:
- A urinary tract infection or prostate inflammation can raise PSA.
- Ejaculation or vigorous cycling in the day or two before a test may raise it temporarily.
- Some medicines used for prostate enlargement can lower PSA, so a doctor needs to know about every medicine a man takes.
Keeping a personal record of each result is also useful. With tests two years apart, a pattern over time often tells a doctor more than any single number.
Why Active Surveillance Matters in Prostate Cancer Care
Some prostate cancers grow so slowly that they never become life-threatening. Treating them right away can expose patients to urinary incontinence, erectile dysfunction and bowel problems, with little or no gain in survival.
For men diagnosed with low-risk prostate cancer, the ACS recommends active surveillance as the first approach. Active surveillance means closely monitoring the cancer instead of treating it immediately. Monitoring involves regular PSA testing, repeat biopsies and, in some cases, MRI scans. Treatment starts if later assessments show the disease is becoming more aggressive.
This approach lets doctors act on cancers that need treatment while sparing other patients, or at least delaying, the side effects of treatment they may never need. In my view, this is the most useful part of the update. Screening finds more cancers, and active surveillance is what keeps that extra detection from turning into extra overtreatment. The two parts of the guideline work as a pair.
How the ACS Developed the New Recommendations
The recommendations followed a systematic review of the scientific evidence and a commissioned modelling study of the benefits and potential harms of PSA-based screening. The guideline development group included clinicians, epidemiologists, biostatisticians and patient representatives. The guidance was published in CA: A Cancer Journal for Clinicians.
Taken together, the update reflects a wider shift in prostate cancer care: earlier detection backed by more careful diagnostic assessment and more considered treatment decisions.
What Men Approaching Screening Age Should Do Next
Men who are approaching screening age, particularly those with recognised risk factors, have good reason to raise prostate cancer screening with a healthcare professional. Before the appointment, a man can write down his age, his race, which relatives have had prostate cancer and at what age, and the medicines he takes. These details determine which row of the table above applies to him.
The final decision should reflect individual risk, overall health and the benefits and limits of testing. Screening can save lives, but it works best when both the man and his doctor understand what a result does and does not mean.



